OBI Pharma, Inc. (TPEX:4174)

OBI Pharma Revenue

OBI Pharma had revenue of 15.28M TWD in the quarter ending June 30, 2026, with 19.77% growth. This brings the company's total for the last twelve months to 52.20M, down -15.45% year-over-year. In the year 2025, OBI Pharma had annual revenue of 58.58M, down -6.55%. That makes OBI Pharma the 42,801st largest company in the world by revenue and 2,146th in Taiwan.

• Revenue (ttm): 52.20M
• Revenue Growth: -15.45%
• P/S Ratio: 132.58
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 6.92B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• CDMO 69.27M 89.0%
• New Anticancer Drug 8.57M 11.0%

By Geography

Chart

• Taiwan 42.16M 72.0%
• Others 16.42M 28.0%

Fiscal year ended Dec 31, 2025 See the full OBI Pharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	58.58M	-4.10M	-6.55%
Dec 31, 2024	62.68M	21.13M	50.85%
Dec 31, 2023	41.55M	36.84M	781.96%
Dec 31, 2022	4.71M	-14.06M	-74.90%
Dec 31, 2021	18.77M	-122.11M	-86.68%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error